atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (Mar 4) ↗ Press Release Readers might remember that atai shared topline
On April 4, 2024, the Colorado General Assembly introduced Senate Bill 24-198, the first legislative update since the passing of SB 23-290 in 2023, which
In early 2023, we visualised our Psychedelics Drug Development Tracker data in a ‘bullseye chart’ format as part of 2022’s Year in Review. Due to its
Pα+: MEP Action Group Meets in Brussels to Discuss Regulatory Pathways for PsychedelicsNovember 8, 2023 Pα+ subscriber content: On Monday, the inaugural meeting of the
Next, Maryam Jabir shared her experience as a participant in a phase 2b study of psilocybin therapy for treatment-resistant depression. Having struggled with depression for
*** One new non-voting participant was introduced in the September meeting of the Qualifications, Licensing, and Training subcommittee. The new participant, Luke Priel, is a
*** One new non-voting participant was introduced in the September meeting of the Qualifications, Licensing, and Training subcommittee. The new participant, Luke Priel, is a
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi
*** One new non-voting participant was introduced in the September meeting of the Qualifications, Licensing, and Training subcommittee. The new participant, Luke Priel, is a
Treating Depression with Psilocybin + Therapy The long-awaited Phase II clinical trial by the Usona Institute was finally published in August. The results are positive and on